Post hocanalysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results

Abstract

Longer term efficacy results in Japanese patients enrolled in PREVAIL demonstrate continued treatment benefit of enzalutamide compared with placebo in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong

“…75 years of age, 5 and in Asian populations. [6][7][8][9] Delayed median time to first skeletal-related event was shown in both chemotherapy-experienced 10 and chemotherapy-naive 11 patients. Reductions across the full range of Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores (P < .001) 12 and delayed health-related quality of life deterioration in chemotherapy-naive patients 13 were reported.…”

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan

“…( 20 ) or the PREVAIL study ( 21 ). The PREVAIL study included Japanese patients and post hoc analysis on a Japanese cohort demonstrate consistency of efficacy and safety results with the overall PREVAIL population ( 22 ). The decrements of utility for patients experiencing SREs or AEs were set by referring to published articles and the PREVAIL study, or were based on assumptions.…”

Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

“…Differences in genetics, environment, lifestyle, diet, and culture are all likely to influence the management of advanced prostate cancer in the APAC region. Some of these differences are highlighted in recent post hoc analyses of data from the PREVAIL trial in different population groups . Whilst numbers are small, differences in the East Asian patients compared with the overall study population included more common upper respiratory tract infection, urinary frequency, falls, and decreased appetite.…”

“…Differences in genetics, environment, lifestyle, diet, and culture are all likely to influence the management of advanced prostate cancer in the APAC region. Some of these differences are highlighted in recent post hoc analyses of data from the PREVAIL trial in different population groups [3][4][5].…”